The company will continue to take advantage of the high-throughput materials synthesis and screening platforms used by its parent company Ilika to extend its materials IP portfolio.
‘We are delighted that the success of our biomedical business has allowed us to create Altrika,’ said Ilika chief executive officer Graeme Purdy, who assumes the same position at Altrika. ‘The rapidly growing medical-device and biotech industries provide a tremendous opportunity to build a strong and capable business providing the truly novel materials to these markets. Making these markets the sole focus of Altrika’s activities will allow it to respond to the dynamic needs of the industry even more effectively.’
Altrika will focus on specific areas of the medical technology field, including wound care, ophthalmology, orthopaedics, cardiology, blood filtration and life-science research and will concentrate on the specific needs of the next generation of products for these markets.
This will be done through in-house development and programmes undertaken in collaboration with some of the world’s leading medical technology companies.
Report highlights significant impact of manufacturing on UK economy
Note to Evil Villain/Dave 2020. Thatcher was PM for _11_ years, from 1979 to 1990 so no one under the age of 34 was even born when she left office....